①Enoki Y*, Watanabe H*, Arake R, Fujimura R, Ishiodori K, Imafuku K, Nishida K, Sugimoto R, Nagao S, Miyamura S, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Maruyama T. Potential therapeutic interventions for chronic kidney disease-associated sarcopenia via indoxyl sulfate-induced mitochondrial dysfunction. J Cachexia Sarcopenia Muscle. *equal contribution (in press)
②Sugimoto R*, Watanabe H*, Ikegami K, Enoki Y, Imafuku T, Sakaguchi Y, Murata M, Nishida K, Miyamura M, Ishima Y, Tanaka M, Matsushita K, Komaba H, Fukagawa M, Otagiri M, Toru Maruyama. The down-regulation of ABCG2, a urate exporter, by parathyroid hormone enhances urate accumulation in secondary hyperparathyroidism. Kidney Int. 91: 658-670 (2017) *equal contribution
③Enoki Y, Watanabe H, Arake R, Sugimoto R, Imafuku T, Tominaga Y, Ishima Y, Kotani S, Nakajima M, Tanaka M, Matsushita K, Fukagawa M, Otagiri M, Maruyama T. Indoxyl sulfate potentiates skeletal muscle atrophy by inducing the oxidative stress-mediated expression of myostatin and atrogin-1. Sci Rep. 6:32084 (2016)
④Tanaka M, Miyamura S, Imafuku T, Tominaga Y, Anraku M, Yamasaki K, Kadowaki D, Ishima Y, Watanabe H, Okuda T, Itoh K, Matsushita K, Fukagawa M, Otagiri M, Maruyama T, Effect of a ferric citrate formulation, a phosphate binder, on oxidative stress in chronic kidney diseases-mineral and bone disorder patients receiving hemodialysis: A pilot study, Biol Pharm Bull, 2016 in press